Clinical Trial Update: A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics [Phase 1]

View source ↗

Summary

Phase 1 study evaluating GS-9973 tablet formulations to assess the impact of acid-reducing agents, food, and relative bioavailability on pharmacokinetics in chr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• GS-9973

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED